Equities

Redsense Medical AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Redsense Medical AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)4.46
  • Today's Change-0.04 / -0.89%
  • Shares traded21.14k
  • 1 Year change-38.06%
  • Beta0.4621
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Redsense Medical AB (publ) is a Sweden-based company, which is primarily involved in the healthcare industry. The Company is active within the field of hemodialysis. It operates as a manufacturer of blood loss detection device that is designed to alarm on blood leakage from the venous blood access. The Company's Redsense system consists of an alarm unit, an extension fiber and a non invasive sensor patch. When the sensor patch is placed over the blood access, it detects any blood coming in contact with the sensor. This can occur if the needle is accidentally dislodged or if blood is leaking during dialysis. The Redsense system is designed to alarm when blood reaches the sensor, so the dialysis caregiver or observing person at home, can apply appropriate action when a venous needle dislodges.

  • Revenue in SEK (TTM)30.67m
  • Net income in SEK302.00k
  • Incorporated2003
  • Employees4.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Miris Holding AB (publ)19.52m-3.93m39.10m9.00--1.81--2.00-8.82-8.8234.3416.180.70331.004.791,952,100.00-14.15-49.33-20.65-97.4785.0390.68-20.12-74.982.20-3.020.00--13.568.3553.96--8.55--
SpectraCure AB (publ)1.42m-53.17m56.79m13.00--0.4084--39.93-0.165-0.1650.00520.24680.012--1.90109,384.60-44.68-13.14-49.10-14.07835.02243.69-3,739.03-592.49---197.290.0325---46.15-13.97-12.54--0.1962--
ScandiDos AB59.37m-1.38m57.01m25.00--1.3292.400.9602-0.0242-0.02421.040.75760.84161.525.602,283,539.00-1.96-8.71-3.04-14.6848.3052.29-2.33-10.670.7927--0.00--2.341.55102.23---11.62--
Neola Medical AB0.00-10.99m57.84m8.00--0.7372-----0.1479-0.14790.001.010.00----0.00-13.81-15.62-14.65-16.86--5,384.30---6,523.935.61--0.00-------11.70--35.63--
Luxbright AB11.49m-19.25m62.08m12.00--2.31--5.40-0.1644-0.16440.09680.20670.27887.732.68---46.74-56.30-59.61-66.28-6.22-79.12-167.60-450.361.22-83.810.1076--26.5279.40-9.86------
Kontigo Care AB29.13m-2.07m62.54m10.00--1.2417.282.15-0.0589-0.05890.82621.430.4487--7.97---3.190.296-3.980.4064125.51129.99-7.120.4638----0.00---3.667.41-367.61--17.15--
Episurf Medical AB15.60m-62.70m69.52m26.00--0.6498--4.46-0.064-0.0640.01570.06450.1641--3.95577,777.80-65.44-45.67-74.89-50.07-----398.72-857.082.50--0.0844--23.5819.3919.83--6.68--
Redsense Medical AB (publ)30.67m302.00k74.00m4.00224.662.06125.212.410.020.021.862.180.76971.966.616,134,600.000.7578-14.280.8514-15.8661.4568.850.9846-32.794.69--0.00--12.8516.26107.58---53.01--
Scandinavian ChemoTech AB11.68m-8.70m75.92m1.00--13.19--6.50-0.3727-0.37270.50030.26530.7270.59172.661,946,333.00-54.15-92.70-83.07-131.4682.15104.65-74.49-866.060.861-5.610.00--132.6763.8534.96---59.68--
Observe Medical ASA15.64m-115.27m87.04m4.00--3.59--5.57-26.57-26.573.290.19090.11182.878.293,350,800.00-82.38-42.22-205.00-64.146.2430.17-737.14-327.970.1175-3.720.9572---33.85153.47-98.73---2.97--
BibbInstruments AB149.00k-13.30m88.81m4.00--2.08--596.05-0.3802-0.38020.00411.050.00382.062.7137,250.00-33.98-36.85-35.53-40.0630.8759.14-8,922.82-22,555.646.67--0.00-------15.85---1.52--
SyntheticMR AB (publ)57.05m-54.93m101.39m41.00--0.6871--1.78-0.9057-0.90570.94671.650.3678--0.87331,391,415.00-35.42-7.92-51.34-10.5110.4156.07-96.28-14.37---8.730.0450--2.473.20-241.50--7.37--
Arcoma AB132.94m4.35m107.03m31.0023.341.469.240.80510.32050.32059.875.131.452.9213.714,288,452.004.752.166.663.7540.4537.953.271.402.04--0.000.00-3.813.24336.0011.08-9.43--
Iconovo AB1.59m-41.23m107.71m19.00--0.4547--67.88-1.67-1.670.05372.460.0117--0.260863,475.20-30.39-28.39-33.14-31.51901.69159.24-2,598.41-295.86---138.020.0391---58.55-24.2210.36--22.28--
Data as of Feb 11 2026. Currency figures normalised to Redsense Medical AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

4.55%Per cent of shares held by top holders
HolderShares% Held
Swedbank Robur Fonder ABas of 30 Dec 2025336.90k2.05%
Aktia Bank Plc (Investment Management)as of 31 Dec 2025310.00k1.89%
Schroder Investment Management (Europe) SA (Finland)as of 30 Jun 2025100.00k0.61%
Evli Fund Management Co. Ltd.as of 30 Aug 20241.00k0.01%
More ▼
Data from 31 Dec 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.